Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
[ad_1] The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s BLUE lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients…